MovDisordV3, Main, Merge, bibRecord, 007F29

Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys

Identifieur interne : 007F29 ( Main/Merge ); précédent : 007F28; suivant : 007F30

Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys

Auteurs : Jay S. Schneider [États-Unis] ; Anne Pope-Coleman [États-Unis] ; Maria Van Velson [États-Unis] ; Frederique Menzaghi [États-Unis] ; G. Kenneth Lloyd [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1998-07.

RBID : ISTEX:66736B6A8305FD28BDC23A3E896D5A4B0A3D881E

English descriptors

KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animals, Antiparkinson Agents (pharmacology), Dose-Response Relationship, Drug, Drug Synergism, Levodopa (pharmacokinetics), L‐dopa, Macaca fascicularis, Male, Monkeys, Motor Skills (drug effects), NAChR, Neurologic Examination (drug effects), Nicotinic Agonists (pharmacology), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (physiopathology), Parkinsonism, Pyridines (pharmacology), Pyrrolidines (pharmacology), Receptors, Cholinergic (physiology), Receptors, Nicotinic (physiology).
MESH :
- chemical , pharmacokinetics : Levodopa.
- chemical , pharmacology : Antiparkinson Agents, Nicotinic Agonists, Pyridines, Pyrrolidines.
- chemical , physiology : Receptors, Cholinergic, Receptors, Nicotinic.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Motor Skills, Neurologic Examination.
- physiopathology : Parkinson Disease, Secondary.
- Animals, Dose-Response Relationship, Drug, Drug Synergism, Macaca fascicularis, Male.

Abstract

The potential antiparkinsonian effects of the centrally acting, subtype‐selective neuronal nicotinic acetylcholine receptor agonist (S)‐(7‐)‐‐5‐ethynyl‐3‐(1‐methyl‐2‐pyrrolidinyl)‐pyridine (SIB‐1508Y) was assessed on motor symptoms and disability scale ratings in three monkeys previously made parkinsonian by chronic exposure to the dopaminergic neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Compared with levodopa (L‐dopa), SIB‐1508Y exerted only mild antiparkinsonian effects when administered alone. Emetic effects of this drug interfered with potential therapeutic effects at higher doses. However, when a low, ineffective dose of SIB‐1508Y was combined with low, ineffective doses of L‐dopa, a significant clinical effect was observed. These data suggest that subtype‐selective nicotinic acetylcholine receptor agonists may hold promise as antiparkinsonian agents, and when administered in combination with L‐dopa may allow a reduction in the dose of L‐dopa needed to achieve a significant clinical effect.

Url:

https://api.istex.fr/document/66736B6A8305FD28BDC23A3E896D5A4B0A3D881E/fulltext/pdf

DOI: 10.1002/mds.870130405

Links to Exploration step

ISTEX:66736B6A8305FD28BDC23A3E896D5A4B0A3D881E

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</title>
<author><name sortKey="Schneider, Jay S" sort="Schneider, Jay S" uniqKey="Schneider J" first="Jay S." last="Schneider">Jay S. Schneider</name>
</author>
<author><name sortKey="Pope Oleman, Anne" sort="Pope Oleman, Anne" uniqKey="Pope Oleman A" first="Anne" last="Pope-Coleman">Anne Pope-Coleman</name>
</author>
<author><name sortKey="Van Velson, Maria" sort="Van Velson, Maria" uniqKey="Van Velson M" first="Maria" last="Van Velson">Maria Van Velson</name>
</author>
<author><name sortKey="Menzaghi, Frederique" sort="Menzaghi, Frederique" uniqKey="Menzaghi F" first="Frederique" last="Menzaghi">Frederique Menzaghi</name>
</author>
<author><name sortKey="Kenneth Lloyd, G" sort="Kenneth Lloyd, G" uniqKey="Kenneth Lloyd G" first="G." last="Kenneth Lloyd">G. Kenneth Lloyd</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:66736B6A8305FD28BDC23A3E896D5A4B0A3D881E</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1002/mds.870130405</idno>
<idno type="url">https://api.istex.fr/document/66736B6A8305FD28BDC23A3E896D5A4B0A3D881E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002249</idno>
<idno type="wicri:Area/Istex/Curation">002249</idno>
<idno type="wicri:Area/Istex/Checkpoint">003752</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Schneider J:effects:of:sib</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:9686767</idno>
<idno type="wicri:Area/PubMed/Corpus">004383</idno>
<idno type="wicri:Area/PubMed/Curation">004383</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004446</idno>
<idno type="wicri:Area/Ncbi/Merge">005000</idno>
<idno type="wicri:Area/Ncbi/Curation">005000</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">005000</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Schneider J:effects:of:sib</idno>
<idno type="wicri:Area/Main/Merge">007F29</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</title>
<author><name sortKey="Schneider, Jay S" sort="Schneider, Jay S" uniqKey="Schneider J" first="Jay S." last="Schneider">Jay S. Schneider</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Pope Oleman, Anne" sort="Pope Oleman, Anne" uniqKey="Pope Oleman A" first="Anne" last="Pope-Coleman">Anne Pope-Coleman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Van Velson, Maria" sort="Van Velson, Maria" uniqKey="Van Velson M" first="Maria" last="Van Velson">Maria Van Velson</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Menzaghi, Frederique" sort="Menzaghi, Frederique" uniqKey="Menzaghi F" first="Frederique" last="Menzaghi">Frederique Menzaghi</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SIBIA Neurosciences, Inc, La Jolla, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kenneth Lloyd, G" sort="Kenneth Lloyd, G" uniqKey="Kenneth Lloyd G" first="G." last="Kenneth Lloyd">G. Kenneth Lloyd</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SIBIA Neurosciences, Inc, La Jolla, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1998-07">1998-07</date>
<biblScope unit="vol">13</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="637">637</biblScope>
<biblScope unit="page" to="642">642</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">66736B6A8305FD28BDC23A3E896D5A4B0A3D881E</idno>
<idno type="DOI">10.1002/mds.870130405</idno>
<idno type="ArticleID">MDS870130405</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Synergism</term>
<term>Levodopa (pharmacokinetics)</term>
<term>L‐dopa</term>
<term>Macaca fascicularis</term>
<term>Male</term>
<term>Monkeys</term>
<term>Motor Skills (drug effects)</term>
<term>NAChR</term>
<term>Neurologic Examination (drug effects)</term>
<term>Nicotinic Agonists (pharmacology)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (physiopathology)</term>
<term>Parkinsonism</term>
<term>Pyridines (pharmacology)</term>
<term>Pyrrolidines (pharmacology)</term>
<term>Receptors, Cholinergic (physiology)</term>
<term>Receptors, Nicotinic (physiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Nicotinic Agonists</term>
<term>Pyridines</term>
<term>Pyrrolidines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Cholinergic</term>
<term>Receptors, Nicotinic</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term>
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Synergism</term>
<term>Macaca fascicularis</term>
<term>Male</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The potential antiparkinsonian effects of the centrally acting, subtype‐selective neuronal nicotinic acetylcholine receptor agonist (S)‐(7‐)‐‐5‐ethynyl‐3‐(1‐methyl‐2‐pyrrolidinyl)‐pyridine (SIB‐1508Y) was assessed on motor symptoms and disability scale ratings in three monkeys previously made parkinsonian by chronic exposure to the dopaminergic neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Compared with levodopa (L‐dopa), SIB‐1508Y exerted only mild antiparkinsonian effects when administered alone. Emetic effects of this drug interfered with potential therapeutic effects at higher doses. However, when a low, ineffective dose of SIB‐1508Y was combined with low, ineffective doses of L‐dopa, a significant clinical effect was observed. These data suggest that subtype‐selective nicotinic acetylcholine receptor agonists may hold promise as antiparkinsonian agents, and when administered in combination with L‐dopa may allow a reduction in the dose of L‐dopa needed to achieve a significant clinical effect.</div>
</front>
</TEI>
<double doi="10.1002/mds.870130405"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</title>
<author><name sortKey="Schneider, Jay S" sort="Schneider, Jay S" uniqKey="Schneider J" first="Jay S." last="Schneider">Jay S. Schneider</name>
</author>
<author><name sortKey="Pope Oleman, Anne" sort="Pope Oleman, Anne" uniqKey="Pope Oleman A" first="Anne" last="Pope-Coleman">Anne Pope-Coleman</name>
</author>
<author><name sortKey="Van Velson, Maria" sort="Van Velson, Maria" uniqKey="Van Velson M" first="Maria" last="Van Velson">Maria Van Velson</name>
</author>
<author><name sortKey="Menzaghi, Frederique" sort="Menzaghi, Frederique" uniqKey="Menzaghi F" first="Frederique" last="Menzaghi">Frederique Menzaghi</name>
</author>
<author><name sortKey="Kenneth Lloyd, G" sort="Kenneth Lloyd, G" uniqKey="Kenneth Lloyd G" first="G." last="Kenneth Lloyd">G. Kenneth Lloyd</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:66736B6A8305FD28BDC23A3E896D5A4B0A3D881E</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1002/mds.870130405</idno>
<idno type="url">https://api.istex.fr/document/66736B6A8305FD28BDC23A3E896D5A4B0A3D881E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002249</idno>
<idno type="wicri:Area/Istex/Curation">002249</idno>
<idno type="wicri:Area/Istex/Checkpoint">003752</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Schneider J:effects:of:sib</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</title>
<author><name sortKey="Schneider, Jay S" sort="Schneider, Jay S" uniqKey="Schneider J" first="Jay S." last="Schneider">Jay S. Schneider</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Pope Oleman, Anne" sort="Pope Oleman, Anne" uniqKey="Pope Oleman A" first="Anne" last="Pope-Coleman">Anne Pope-Coleman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Van Velson, Maria" sort="Van Velson, Maria" uniqKey="Van Velson M" first="Maria" last="Van Velson">Maria Van Velson</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Menzaghi, Frederique" sort="Menzaghi, Frederique" uniqKey="Menzaghi F" first="Frederique" last="Menzaghi">Frederique Menzaghi</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SIBIA Neurosciences, Inc, La Jolla, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kenneth Lloyd, G" sort="Kenneth Lloyd, G" uniqKey="Kenneth Lloyd G" first="G." last="Kenneth Lloyd">G. Kenneth Lloyd</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SIBIA Neurosciences, Inc, La Jolla, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1998-07">1998-07</date>
<biblScope unit="vol">13</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="637">637</biblScope>
<biblScope unit="page" to="642">642</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">66736B6A8305FD28BDC23A3E896D5A4B0A3D881E</idno>
<idno type="DOI">10.1002/mds.870130405</idno>
<idno type="ArticleID">MDS870130405</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa</term>
<term>Monkeys</term>
<term>NAChR</term>
<term>Parkinsonism</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The potential antiparkinsonian effects of the centrally acting, subtype‐selective neuronal nicotinic acetylcholine receptor agonist (S)‐(7‐)‐‐5‐ethynyl‐3‐(1‐methyl‐2‐pyrrolidinyl)‐pyridine (SIB‐1508Y) was assessed on motor symptoms and disability scale ratings in three monkeys previously made parkinsonian by chronic exposure to the dopaminergic neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Compared with levodopa (L‐dopa), SIB‐1508Y exerted only mild antiparkinsonian effects when administered alone. Emetic effects of this drug interfered with potential therapeutic effects at higher doses. However, when a low, ineffective dose of SIB‐1508Y was combined with low, ineffective doses of L‐dopa, a significant clinical effect was observed. These data suggest that subtype‐selective nicotinic acetylcholine receptor agonists may hold promise as antiparkinsonian agents, and when administered in combination with L‐dopa may allow a reduction in the dose of L‐dopa needed to achieve a significant clinical effect.</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.</title>
<author><name sortKey="Schneider, J S" sort="Schneider, J S" uniqKey="Schneider J" first="J S" last="Schneider">J S Schneider</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107</wicri:regionArea>
<wicri:noRegion>Pennsylvania 19107</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pope Coleman, A" sort="Pope Coleman, A" uniqKey="Pope Coleman A" first="A" last="Pope-Coleman">A. Pope-Coleman</name>
</author>
<author><name sortKey="Van Velson, M" sort="Van Velson, M" uniqKey="Van Velson M" first="M" last="Van Velson">M. Van Velson</name>
</author>
<author><name sortKey="Menzaghi, F" sort="Menzaghi, F" uniqKey="Menzaghi F" first="F" last="Menzaghi">F. Menzaghi</name>
</author>
<author><name sortKey="Lloyd, G K" sort="Lloyd, G K" uniqKey="Lloyd G" first="G K" last="Lloyd">G K Lloyd</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9686767</idno>
<idno type="pmid">9686767</idno>
<idno type="doi">10.1002/mds.870130405</idno>
<idno type="wicri:Area/PubMed/Corpus">004383</idno>
<idno type="wicri:Area/PubMed/Curation">004383</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004446</idno>
<idno type="wicri:Area/Ncbi/Merge">005000</idno>
<idno type="wicri:Area/Ncbi/Curation">005000</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">005000</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Schneider J:effects:of:sib</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.</title>
<author><name sortKey="Schneider, J S" sort="Schneider, J S" uniqKey="Schneider J" first="J S" last="Schneider">J S Schneider</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107</wicri:regionArea>
<wicri:noRegion>Pennsylvania 19107</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pope Coleman, A" sort="Pope Coleman, A" uniqKey="Pope Coleman A" first="A" last="Pope-Coleman">A. Pope-Coleman</name>
</author>
<author><name sortKey="Van Velson, M" sort="Van Velson, M" uniqKey="Van Velson M" first="M" last="Van Velson">M. Van Velson</name>
</author>
<author><name sortKey="Menzaghi, F" sort="Menzaghi, F" uniqKey="Menzaghi F" first="F" last="Menzaghi">F. Menzaghi</name>
</author>
<author><name sortKey="Lloyd, G K" sort="Lloyd, G K" uniqKey="Lloyd G" first="G K" last="Lloyd">G K Lloyd</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Synergism</term>
<term>Levodopa (pharmacokinetics)</term>
<term>Macaca fascicularis</term>
<term>Male</term>
<term>Motor Skills (drug effects)</term>
<term>Neurologic Examination (drug effects)</term>
<term>Nicotinic Agonists (pharmacology)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (physiopathology)</term>
<term>Pyridines (pharmacology)</term>
<term>Pyrrolidines (pharmacology)</term>
<term>Receptors, Cholinergic (physiology)</term>
<term>Receptors, Nicotinic (physiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Nicotinic Agonists</term>
<term>Pyridines</term>
<term>Pyrrolidines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Cholinergic</term>
<term>Receptors, Nicotinic</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term>
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Synergism</term>
<term>Macaca fascicularis</term>
<term>Male</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The potential antiparkinsonian effects of the centrally acting, subtype-selective neuronal nicotinic acetylcholine receptor agonist (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)-pyridine (SIB-1508Y) was assessed on motor symptoms and disability scale ratings in three monkeys previously made parkinsonian by chronic exposure to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Compared with levodopa (L-dopa), SIB-1508Y exerted only mild antiparkinsonian effects when administered alone. Emetic effects of this drug interfered with potential therapeutic effects at higher doses. However, when a low, ineffective dose of SIB-1508Y was combined with low, ineffective doses of L-dopa, a significant clinical effect was observed. These data suggest that subtype-selective nicotinic acetylcholine receptor agonists may hold promise as antiparkinsonian agents, and when administered in combination with L-dopa may allow a reduction in the dose of L-dopa needed to achieve a significant clinical effect.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007F29 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007F29 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     ISTEX:66736B6A8305FD28BDC23A3E896D5A4B0A3D881E
   |texte=   Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys

Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.